NeoImmuneTech (950220) Q2 2024 earnings summary

Executive summary

• Focuses on T cell-based immunotherapy R&D, with NT-I7 as the lead candidate in multiple clinical trials for cancer and rare diseases.

• No commercial sales yet; revenue generation is expected through licensing, partnerships, and future product launches.

• Maintains robust R&D pipeline, including collaborations with global pharma and research institutions.

Financial highlights

• No operating revenue for the half-year ended June 30, 2024; company remains pre-commercial.

• Operating loss for H1 2024 was USD 15.3 million, compared to USD 22.3 million in H1 2023.

• Net loss for H1 2024 was USD 16.0 million, improved from USD 22.0 million in H1 2023.

• Cash and cash equivalents at June 30, 2024: USD 37.7 million, down from USD 53.3 million at year-end 2023.

• R&D expenses for H1 2024 totaled USD 10.3 million (consolidated), with R&D intensity remaining high.

Outlook and guidance

• Continues to prioritize clinical development and licensing opportunities for NT-I7 and pipeline assets.

• Expects to generate revenue through licensing deals and potential product launches pending clinical success.

• Focus on expanding global clinical trials and advancing ARS (Acute Radiation Syndrome) therapy with US government collaboration.